SCHEMBL30380452

SCHEMBL30380452

CN(OCCCN1CCN(C(=O)OCc2ccccc2)CC1)C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 3/20 0.47
HRH2 P25021 2/20 0.47
SIGMAR1 Q99720 5/20 0.46
TEAD3 Q99594 1/20 0.46
HTR2A P28223 2/20 0.46
OPRM1 P35372 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
HTR7 P34969 1/20 0.46
HTR1A P08908 1/20 0.44
DRD4 P21917 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30802045 0.86 SIGMAR1 (0.48) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL30802046 0.86 SIGMAR1 (0.48) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL25977461 0.82 SIGMAR1 (0.45) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL21528055 0.82 MEN1 (0.51) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL29132198 0.81 MEN1 (0.58) SIGMAR1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL29207863 0.81 SIGMAR1 (0.52) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL25369881 0.80 SIGMAR1 (0.51) HRH1HRH2SIGMAR1HTR2AOPRM1
SCHEMBL21997547 0.80 ACKR3 (0.48) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL21751831 0.79 HRH2 (0.46) HRH1HRH2SIGMAR1TEAD3HTR2A
SCHEMBL28868788 0.79 BCHE (0.50) HRH1HRH2SIGMAR1TEAD3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-01-30 US disclosed
WO-2023059583-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE AURKB, CDK9, AURKA HRH1 2524/4885HRH2 3232/4885SIGMAR1 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.